Pathogenesis of immune-mediated neuropathies

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1852, Issue 4, 2015, Pages 658-666

  Dalakas, Marinos C ^a,b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Autoimmunity; Immunotherapy; Neuropathy; Ranvier

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; BELIMUMAB; BETA INTERFERON; BIOLOGICAL MARKER; BIOLOGICAL PRODUCT; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOKINE; DACLIZUMAB; ECULIZUMAB; FINGOLIMOD; GANGLIOSIDE ANTIBODY; GANGLIOSIDE GM1; GANGLIOSIDE GM1 ANTIBODY; GLYCOLIPID; GLYCOPROTEIN; GLYCOSPHINGOLIPID; HUMORAL ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOGLOBULIN M ANTIBODY; JANUS KINASE; METHOTREXATE; MYCOPHENOLIC ACID; NATALIZUMAB; RITUXIMAB; TOFACITINIB; AUTOANTIBODY; NERVE PROTEIN;

AUTOIMMUNE DISEASE; B LYMPHOCYTE; CELL ADHESION; CELL MIGRATION; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; DEMYELINATION; GUILLAIN BARRE SYNDROME; HAPLOTYPE; HUMAN; IMMUNOPATHOGENESIS; IMMUNOPATHOLOGY; IMMUNOTHERAPY; INTRACELLULAR SIGNALING; LYMPHOCYTE MIGRATION; MOLECULAR MIMICRY; MOLECULE; MOTOR NEUROPATHY; MYELIN SHEATH; NERVE BLOCK; NEUROPATHY; OPHTHALMOPLEGIA; PARAPROTEINEMIA; PATHOGENESIS; PLASMAPHERESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN BIOPSY; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; ULCERATIVE COLITIS; UPREGULATION; IMMUNOLOGY; MOTOR NEURON DISEASE; PATHOLOGY; POLYRADICULONEUROPATHY;

AUTOANTIBODIES; GUILLAIN-BARRE SYNDROME; HUMANS; MOTOR NEURON DISEASE; NERVE TISSUE PROTEINS; POLYRADICULONEUROPATHY, CHRONIC INFLAMMATORY DEMYELINATING; T-LYMPHOCYTES;

EID: 84922337248     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2014.06.013     Document Type: Review

References (94)

1. Dalakas M.C. Autoimmune peripheral neuropathies. Clinical Immunology: Principles and Practice 2011, 977-994. Mosby Elsevier, Philadelphia. edn. 3. R.R. Rich, T.A. Fleisher, W.T. Shearer (Eds.).
2. Dalakas M.C. Pathophysiology of Autoimmune Polyneuropathies Presse Medicale 2013.
3. Yuki N., Hartung H.P. Guillain-Barré syndrome. N. Engl. J. Med. 2012, 366:2294-2304.
4. Hughes R.A., Cornblath D.R. Guillain-Barré syndrome. Lancet 2005, 366:1653-1666.
5. Winer J.B. Guillain-Barré syndrome: clinical variants and their pathogenesis. J. Neuroimmunol. 2011, 231(1-2):70-72.
6. Feasby T.E., Hahn A.F., Brown W.F., Bolton C.F., Gilbert J.J., Koopman W.J. Severe axonal degeneration in acute Guillain-Barré syndrome: evidence of two different mechanisms?. J. Neurol. Sci. 1993, 116:185-192.
7. Yuki N., Susuki K., Koga M., Nishimoto Y., Odaka M., Hirata K., et al. Carbohydrate mimicry between human ganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes Guillain-Barré syndrome. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:11404-11409.
8. Willison H.J., Yuki N. Peripheral neuropathies and anti-glycolipid antibodies. Brain 2002, 125:2591-2625.
9. Kusunoki S., Kaida K. Antibodies against ganglioside complexes in Guillain-Barré syndrome and related disorders. J. Neurochem. 2011, 116:828-832.
10. Dalakas M.C. Advances in the diagnosis, pathogenesis and treatment of CIDP. Nat. Rev. Neurol. 2011, 7:507-517.
11. Lunn M.P., Manji H., Choudhary P.P., Hughes R.A., Thomas P.K. Chronic inflammatory demyelinating polyradiculoneuropathy: a prevalence study in south east England. J. Neurol. Neurosurg. Psychiatry 1999, 66:677-680.
12. Hughes R.A.C., Allen D., Makowska A., Gregson N.A. Pathogenesis of chronic inflammatory demyelinating polyradiculoneuropathy. J. Peripher. Nerv. Syst. 2006, 11:30-46.
13. Vallat J.M., Sommer C., Magy L. Chronic inflammatory demyelinating polyradiculoneuropathy: diagnostic and therapeutic challenges for a treatable condition. Lancet Neurol. 2010, 9:402-412.
14. Sommer C., Koch S., Lammens M., Gabreels-Festen A., Stoll G., Toyka K.V. Macrophage clustering as a diagnostic marker in sural nerve biopsies of patients with CIDP. Neurology 2005, 65:1924-1929.
15. Vital C., Vital A., Lagueny A., Ferrer X., Fontan D., Barat M., et al. Chronic inflammatory demyelinating polyneuropathy: immunopathological and ultrastructural study of peripheral nerve biopsy in 42 cases. Ultrastruct. Pathol. 2000, 24:363-369.
16. Koller H., Kieseier B.C., Jander S., Hartung H.P. Chronic inflammatory demyelinating polyneuropathy. N. Engl. J. Med. 2005, 352:1343-1356.
17. Van Asseldonk J.T., Franssen H., Van den Berg-Vos R.M., Wokke J.H., Van den Berg L.H. Multifocal motor neuropathy. Lancet Neurol. 2005, 4:309-319.
18. Yuki N., Watanabe H., Nakajima T., Späth P.J. IVIG blocks complement deposition mediated by anti-GM1 antibodies in multifocal motor neuropathy. J. Neurol. Neurosurg. Psychiatry Jan 2011, 82(1):87-91.
19. Dalakas M.C., Quarles R.H. Autoimmune ataxic neuropathies (sensory ganglionopathies): are glycolipids the responsible autoantigens?. Ann. Neurol. 1996, 39:419-422. Editorial.
20. Illa I., Ortiz N., Gallard E., Juarez C., Grau J.M., Dalakas M.C. Acute axonal Guillain-Barré syndrome with IgG antibodies against motor axons following parenteral gangliosides. Ann. Neurol. 1995, 38:218-224.
21. Ang C.W., Jacobs B.C., Laman J.D. The Guillain-Barré syndrome: a true case of molecular mimicry. Trends Immunol. 2004, 25:61-66.
22. Prineas J.W., McLeod J.G. Chronic relapsing polyneuritis. J. Neurol. Sci. 1976, 27:427-458.
23. Dalakas M.C. Advances in chronic inflammatory demyelinating polyneuropathy: disease variants and inflammatory response mediators and modifiers. Curr. Opin. Neurol. 1999, 12:403-409.
24. Murata K., Dalakas M.C. Expression of the co-stimulatory molecule BB-1, the ligands CTLA-4 and CD28 and their mRNAs in chronic inflammatory demyelinating polyneuropathy. Brain 2000, 123:1660-1666.
25. Kiefer R., Dangond F., Mueller M., Toyka K.V., Hafler D.A., Hartung H.P. Enhanced B7 costimulatory molecule expression in infl ammatory human sural nerve biopsies. J. Neurol. Neurosurg. Psychiatry 2000, 69:362-368.
26. Kieseier B.C., Tani M., Mahad D., Oka N., Ho T., Woodroofe N., et al. Chemokines and chemokine receptors in inflammatory demyelinating neuropathies: a central role for IP-10. Brain 2002, 125:823-834.
27. Hu W., Janke A., Ortler S., Hartung H.P., Leder C., Kieseier B.C., et al. Expression of CD28-related costimulatory molecule and its ligand in inflammatory neuropathies. Neurology 2007, 68:277-282.
28. Salomon B., Rhee L., Bour-Jordan H., Hsin H., Montag A., Soliven B., Soliven B., et al. Development of spontaneous autoimmune peripheral polyneuropathy in B7-2-deficient NOD mice. J. Exp. Med. 2001, 194:677-684.
29. Schneider-Hohendorf T., Schwab N., Uçeyler N., Göbel K., Sommer C., Wiendl H. CD8+ T-cell immunity in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 2012, 78:402-408.
30. Mausberg A.K., Dorok M., Stettner M., Müller M., Hartung H.P., Dehmel T., et al. Recovery of the T-cell repertoire in CIDP by IV immunoglobulins. Neurology 2013, 80(3):296-303.
31. Dalakas M.C. Mechanistic effects of IVIg in neuroinflammatory diseases: conclusions based on clinicopathologic correlations. J. Clin. Immunol. 2014, 34(Suppl 1):120-126.
32. Chi L.J., Xu W.H., Zhang Z.W., Huang H.T., Zhang L.M., Zhou J. Distribution of Th17 cells and Th1 cells in peripheral blood and cerebrospinal fluid in chronic inflammatory demyelinating polyradiculoneuropathy. J. Peripher. Nerv. Syst. 2010, 15:345-356.
33. Chi L.J., Wang H.B., Wang W.Z. Impairment of circulating CD4+CD25+ regulatory T cells in patients with chronic inflammatory demyelinating polyradiculoneuropathy. J. Peripher. Nerv. Syst. 2008, 13:54-63.
34. Sanvito L., Makowska A., Gregson N., Nemni R., Hughes R.A. Circulating subsets and CD4(+)CD25(+) regulatory T cell function in chronic inflammatory demyelinating polyradiculoneuropathy. Autoimmunity 2009, 42:667-677.
35. Hartung H.P., Reiners K., Schmidt B., Stoll G., Toyka K.V. Serum interleukin-2 concentrations in Guillain-Barre syndrome and chronic idiopathic demyelinating polyradiculoneuropathy: comparison with other neurological diseases of presumed immunopathogenesis. Ann. Neurol. 1991, 30:48-53.
36. Mahad D.J., Howell S.J., Woodroofe M.N. Expression of chemokines in cerebrospinal fluid and serum of patients with chronic inflammatory demyelinating polyneuropathy. J. Neurol. Neurosurg. Psychiatry 2002, 73:320-323.
37. Maimone D., Annunziata P., Simone I.L., Livrea P., Guazzi G.C. Interleukin-6 levels in the cerebrospinal fluid and serum of patients with Guillain-Barre syndrome and chronic inflammatory demyelinating polyradiculoneuropathy. J. Neuroimmunol. 1993, 47:55-61.
38. Oka N., Akiguchi I., Nagao M., Nishio T., Kawasaki T., Kimura J. Expression of endothelial leukocyte adhesion molecule-1 (ELAM-1) in chronic inflammatory demyelinating polyneuropathy. Neurology 1994, 44:946-950.
39. Renaud S., Hays A.P., Brannagan T.H., Sander H.W., Edgar M., Weimer L.H., et al. Gene expression profiling in chronic inflammatory demyelinating polyneuropathy. J. Neuroimmunol. 2005, 159(1-2):203-214.
40. Lee G., Xiang Z., Brannagan T.H., Chin R.L., Latov N. Differential gene expression in chronic inflammatory demyelinating polyneuropathy (CIDP) skin biopsies. J. Neurol. Sci. 2010, 290(1-2):115-122.
41. Dalakas M.C., Engel W.K. Immunoglobulin and complement deposits in nerves of patients with chronic relapsing polyneuropathy. Arch. Neurol. 1980, 37:637-640.
42. Dalakas M., Houff S.A., Engel W.K., Madden D.L., Sever J.L. CSF monoclonal bands in chronic relapsing polyneuropathy. Neurology 1980, 30:864-867.
43. Ilyas A.A., Mitchen F.A., Dalakas M.C., Chen Z.W., Cook S.D. Antibodies to acidic glycolipids in Guillain Barre' syndrome and chronic inflammatory demyelinating polyneuropathy. J. Neurol. Sci. 1992, 107:1111-1211.
44. Tagawa Y., Yuki N., Hirata K. Anti-SGPG antibody in CIDP: a nosological position of IgM anti-MAG/SGPG antibody-associated neuropathy. Muscle Nerve 2000, 23:895-899.
45. Yan W.X., Taylor J., Andrias-Kauba S., Pollard J.D. Passive transfer of demyelination by serum or IgG from chronic inflammatory demyelinating polyneuropathy patients. Ann. Neurol. 2000, 47:765-775.
46. Yan W.X., Archelos J.J., Hartung H.P., Pollard J.D. P0 protein is a target antigen in chronic infl ammatory demyelinating polyradiculoneuropathy. Ann. Neurol. 2001, 50:286-292.
47. Tackenberg B., Jelcic I., Baerenwaldt A., Oertel W.H., Sommer N., Nimmerjahn F., et al. Impaired inhibitory Fcgamma receptor IIB expression on B cells in chronic infl ammatory demyelinating polyneuropathy. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:4788-4792.
48. Bird S.J., Brown M.J., Shy M.E., Scherer S.S. Chronic inflammatory demyelinating polyneuropathy associated with malignant melanoma. Neurology 1996, 46:822-824.
49. Weiss M.D., Luciano C.A., Semino-Mora C., Dalakas M.C., Quarles R.H. Molecular mimicry in chronic inflammatory demyelinating polyneuropathy and melanoma. Neurology 1998, 51:1738-1741.
50. Pollard J.D., Armati P.J. CIDP-the relevance of recent advances in Schwanncell/axonal neurobiology. J. Peripher. Nerv. Syst. 2011, 16:15-23.
51. Cifuentes-Diaz Carmen, Dubourg O., Irinopoulou T., Vigny M., Lachkar S., Decker L., et al. Nodes of Ranvier and paranodes in chronic acquired neuropathies. PLoS ONE 2011, 6:e14533.
52. Lonigro A., Devaux J.J. Disruption of neurofascin and gliomedin at nodes of Ranvier precedes demyelination in experimental allergic neuritis. Brain 2009, 132:260-273.
53. Susuki K. Node of Ranvier disruption as a cause of neurological diseases. ASN Neuro Aug. 7 2013, 5(3):209-219.
54. Devaux J.J., Odaka M., Yuki N. Nodal proteins are target antigens in Guillain-Barré syndrome. J. Peripher. Nerv. Syst. 2012, 17:62-71.
55. Yan W.X., Mathey E., Yiannikas C., Pollard J. Antineurofascin antibodies are present in patients with peripheral demyelinating neuropathies and mediate changes in nerve conduction in animals. J. Peripher. Nerv. Syst. 2010, 15:288-289.
56. Kawamura N., Yamasaki R., Yonekawa T., Matsushita T., Kusunoki S., Nagayama S., Fukuda Y., Ogata H., Matsuse D., Murai H., Kira J. Anti-neurofascin antibody in patients with combined central and peripheral demyelination. Neurology 2013, 81:714-722.
57. Ng J.K., Malotka J., Kawakami N., Derfuss T., Khademi M., Olsson T., et al. Neurofascin as a target for autoantibodies in peripheral neuropathies. Neurology 2012, 79:2241-2248.
58. Querol L., Nogales-Gadea G., Rojas-Garcia R., Martinez-Hernandez E., Diaz-Manera J., Suarez-Calvet X., Navas M., Araque J., Gallardo E., Illa I. Antibody to contactin-1 in chronic inflammatory demyelinating polyneuropathy. Ann. Neurol. 2013, 73:370-380.
59. Querol L., Rojas-Garcia R., Diaz-Manera J., Pardo J., Sedano M.J., Gallardo E., Berciano J., Blesa R., Dalmau J., Illa I. Neurofascin IgG4 antibodies in CIDP associate with disabling tremor and poor response to IVIg. Neurology 2013, 2014.
60. Iijima M., Tomita M., Morozumi S., Kawagashira Y., Nakamura T., Koike H., et al. Single nucleotide polymorphism of TAG-1 influences IVIg responsiveness of Japanese patients with CIDP. Neurology 2009, 73:1348-1352.
61. Alexopoulos H., Pavlakis P.P., Karagogeos D., Karageorgiou C.E., Dalakas M.C. Are anti-TAG-1 autoantibodies markers in autoimmune demyelinating disorders of the PNS and CNS?. Ann. Neurol. 2011, 70(Suppl. 15):S73.
62. Pavlakis P.P., Alexopoulos H., Karagogeos D., Dalakas M.C. Search for nodal and paranodal autoantibodies in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP). Neurology 2012, 78:P05.159.
63. Stathopoulos P., Alexopoulos H., Biba A., Karagogeos D., Dalakas M.C. Search for autoantibodies targeting the nodes of Ranvier in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 2014, 82(10). (Suppl p.1.028).
64. Dalakas M.C., Engel W.K. Polyneuropathy and monoclonal gammopathy: studies of 11 patients. Ann. Neurol. 1981, 10:45-52.
65. Latov N., Braun P.E., Gross R.B., Sherman W.H., Penn A.S., Chess L. Plasma cell dyscrasia and peripheral neuropathy: identification of the myelin antigens that react with human paraproteins. Proc. Natl. Acad. Sci. U. S. A. 1981, 78:7139.
66. Latov N., Hays A., Sherman W.H. Peripheral neuropathy and anti-MAG antibodies. Crit. Rev. Neurobiol. 1988, 3:301-332.
67. Ilyas A.A., Quarles R.H., McIntosh T.D., Dobersen M.J., Trapp B.D., Dalakas M.C., et al. IgM in a human neuropathy related to paraproteinemia binds to a carbohydrate determinant in the myelin-associated glycoprotein and to a ganglioside. Proc. Natl. Acad. Sci. U. S. A. 1984, 81:1225-1229.
68. Ilyas A.A., Quarles R.H., Dalakas M.C., Brady R.O. Polyneuropathy with monoclonal gammopathy: glycolipids are frequently antigens for IgM paraproteins. Proc. Natl. Acad. Sci. U. S. A. 1985, 82:6697-6700.
69. Duane G.C., Farrer R.G., Dalakas M.C., Quarles R.H. Sensory neuropathy associated with monoclonal IgM to GD1b ganglioside. Ann. Neurol. 1992, 31:683-685.
70. Quarles R.H., Dalakas M.C. Do antiganglioside antibodies cause human peripheral neuropathies?. J. Clin. Invest. 1996, 97:1136-1137.
71. Monaco S., Bonetti B., Ferrari S., Moretto G., Nardelli E., Tedesco F., et al. Complement dependent demyelination in patients with IgM monoclonal gammopathy and polyneuropathy. N. Engl. J. Med. 1990, 322:844-852.
72. Lombardi R., Erne B., Lauria G., Lauria G., Pareyson D., Borgna M., Morbin M., et al. IgM deposits on skin nerves in anti-myelin-associated glycoprotein neuropathy. Ann. Neurol. 2005, 57:180-187.
73. Willison H.J., Trapp B.D., Bacher J.D., Dalakas M.C., Griffin J.W., Quarles R.H. Demyelination induced by intraneural injection of human antimyelin associated glycoprotein antibodies. Muscle Nerve 1988, 11:1169-1176.
74. Tatum A.H. Experimental paraprotein neuropathy; demyelination by passive transfer of human IgM anti-MAG. Ann. Neurol. 1993, 33:502-506.
75. Ilyas A.A., Gu Y., Dalakas M.C., Quarles R.H., Bhatt S. Induction of experimental ataxic sensory neuronopathy in cats by immunization with purified SGPG. J. Neuroimmunol. 2008, 193:87-93.
76. Hughes R.A., Wijdicks E.F., Barohn R., Benson E., Cornblath D.R., Hahn A.F., et al. Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: immunotherapy for Guillain-Barré syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2003, 61:736-740.
77. Hughes R.A.C., Donofrio P., Bril V., Dalakas M.C., Deng C., Hanna K., et al. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol. 2008, 7:136-144.
78. Dyck P.J., Litchy W.J., Kratz K.M., Suarez G.A., Low P.A., Pineda A.A., et al. A plasma exchange versus immune globulin infusion trial in chronic infl amatory demyelinating polyradiculoneuropathy. Ann. Neurol. 1994, 36:838-845.
79. Dalakas M.C., Quarles R.H., Farrer R.G., Dambrosia J., Soueidan S., Stein D.P., et al. A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy. Ann. Neurol. 1996, 40:792-795.
80. Dalakas M.C., Rakocevic G., Salajegheh M., Dambrosia J.M., Hahn A.F., Raju R., et al. Placebo-controlled trial of rituximab in IgM anti-myelin associated glycoprotein antibody demyelinating neuropathy. Ann. Neurol. 2009, 65:286-293.
81. Mahdi-Rodgers M., Swan A.V., van Doorn P.A., Hughes R.A.C. Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for CIDP. Cochrane Database Syst. Rev. 2010, (Issue 11).
82. Hughes R.A., Gorson K.C., Cros D., Griffin J., Pollard J., Vallat J.M., et al. Intramuscular interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 2010, 74:651-657.
83. RMC Trial Group Randomised controlled trial of methotrexate for chronic infl ammatory demyelinating polyradiculoneuropathy (RMC trial): a pilot, multicentre study. Lancet Neurol. 2009, 8:158-164.
84. Dalakas M.C. Potential biomarkers for monitoring therapeutic responses to IVIg and other therapies in CIDP. J. Peripher. Nerv. Syst. 2011, (Suppl. 1):63-67.
85. Kuitwaard K., de Gelder J., Tio-Gillen A.P., Hop W.C., van Gelder T., van Toorenenbergen A.W., et al. Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barré syndrome. Ann. Neurol. 2009, 66:597-603.
86. Léger J.M., Viala K., Nicolas G., Créange A., Vallat J.M., Pouget J., Clavelou P., Vial C., Steck A., Musset L., Marin B. Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein neuropathy. Neurology Jun 11 2013, 80(24):2217-2225. RIMAG Study Group (France and Switzerland), (Epub 2013). 10.1212/WNL.0b013e318296e92b.
87. Dalakas M.C. Biologics and other novel approaches as new therapeutic options in myasthenia gravis: a view to the future. Ann. N. Y. Acad. Sci. 2012, 1274:1-8.
88. Dalakas M.C. Novel future therapeutic options in myasthenia gravis. Autoimmun. Rev. 2013, 12(9):936-941.
89. Dalakas M.C. B cells as therapeutic targets in autoimmune neurological disorders. Nat. Clin. Pract. Neurol. 2008, 4:557-567.
90. Benedetti L., Briani C., Franciotta D., Fazio R., Paolasso I., Comi C., et al. Rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a report of 13 cases and review of the literature. J. Neurol. Neurosurg. Psychiatry 2011, 82:306-308.
91. Kosmidis M., Dalakas M.C. Practical considerations on the use of rituximab in autoimmune neurological disorders. Ther. Adv. Neurol. Disord. 2010, 3:93-105.
92. Fitzpatrick A.M., Mann C.A., Barry S., Brennan K., Overell J.R., Willison H.J. An open label clinical trial of complement inhibition in multifocal motor neuropathy. J. Peripher. Nerv. Syst. 2011 Jun, 16(2):84-91.
93. Howard J.F., Barohn R.J., Cutter G.R., Freimer M., Juel V.C., Mozaffar T., Mellion M.L., Benatar M.G., Farrugia M.E., Wang J.J., Malhotra S.S., Kissel J.T., MG Study Group A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis. Muscle Nerve 2013 Jul, 48(1):76-84. 10.1002/mus.23839. Epub 2013 Apr 30.
94. Wolf C., Menge T., Stenner M.P., Meyer zu Hörste G., Saleh A., Hartung H.P., et al. Natalizumab treatment in a patient with chronic inflammatory demyelinating polyneuropathy. Arch. Neurol. 2010, 67:881-883.